hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Durvalumab (Imfinzi) is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
=== Biological === The Culture is a posthuman society, which originally arose when seven or eight roughly humanoid space-faring species coalesced into a quasi-collective (a group-civilisation) ultimately consisting of approximately thirty trillion (short scale) sentient and sapient beings (this includes artificial intelligences). In Banks's universe, a good part (but by no means an overwhelming percentage) of all sentient species is of the "pan-human" type, as noted in Matter. Although the Culture was originated by humanoid species, subsequent interactions with other civilisations have introduced many non-humanoid species into the Culture (including some former enemy civilisations), though the majority of the biological Culture is still pan-human. Little uniformity exists in the Culture, and its citizens are such by choice, free to change physical form and even species (though some stranger biological conversions are irreversible, and conversion from biological to artificial sentience is considered to be what is known as an Unusual Life Choice). All members are also free to join, leave, and rejoin, or indeed declare themselves to be, say, 80% Culture. Within the novels, opponents of the Culture have argued that the role of humans in the Culture is nothing more than that of pets, or parasites on Culture Minds, and that they can have nothing genuinely useful to contribute to a society where science is close to omniscient about the physical universe, where every ailment has been cured, and where every thought can be read.
=== Australia === Australia has documented 10 cases of healthcare-acquired CJD (iatrogenic or ICJD). Five of the deaths resulted after the patients, who were in treatment either for infertility or short stature, were treated using contaminated pituitary extract hormone but no new cases have been noted since 1991. The other five deaths occurred due to dura mater grafting procedures that were performed during brain surgery, in which the covering of the brain is repaired. There have been no other ICJD deaths documented in Australia due to transmission during healthcare procedures.
== External links == Space filling 3D model and ball & stick 3D model full motion animated rotating of Acetorphine/Acetyletorphine 2D nonanimated/nonmoving rendering of Acetorphine/Acetyletorphine as a flat diagram
=== Legal status === The U.S. Food and Drug Administration (FDA) granted orphan drug designations in 2010 and 2020, and breakthrough therapy designation in 2016, on the basis of preliminary data from the phase II trial. In July 2020, and again in November 2020, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for emapalumab. In June 2025, the FDA approved emapalumab-lzsg for the treatment of macrophage activation syndrome (MAS) in patients with Still’s disease.
Sources: en.wikipedia.org
Nevertheless, the site of protonation is very important for biological function, so mathematical methods have been developed for the determination of micro-constants. When two reactants form a single product in parallel, the macro-constant
The Industrial Revolution was the major technological, socioeconomic, and cultural change in late 18th and early 19th century that began in Britain and spread throughout the world. During that time, an economy based on manual labour was replaced by one dominated by industry and the manufacture of machinery. It began with the mechanisation of the textile industries and the development of iron-making techniques, and trade expansion was enabled by the introduction of canals, improved roads, and then railways. The introduction of steam power (fuelled primarily by coal) and powered machinery (mainly in textile manufacturing) underpinned the dramatic increases in production capacity. The development of all-metal machine tools in the first two decades of the 19th century facilitated the manufacture of more production machines for manufacturing in other industries. The date of the Industrial Revolution is not exact. Eric Hobsbawm held that it "broke out" in the 1780s and was not fully felt until the 1830s or 1840s, while T. S. Ashton held that it occurred roughly between 1760 and 1830 (in effect the reigns of George III, The Regency, and George IV). The effects spread throughout Western Europe and North America during the 19th century, eventually affecting the majority of the world. The impact of this change on society was enormous and is often compared to the Neolithic Revolution, when mankind developed agriculture and gave up its nomadic lifestyle.
== Biography == Stephen Kent received his chemistry Ph.D. from the University of California, Berkeley in 1975, his M.Sc. from Massey University, Palmerston North, New Zealand in 1970, and his B.Sc. degree in 1968 from Victoria University of Wellington, New Zealand. Following post-doctoral work in the laboratory of Robert Bruce Merrifield at the Rockefeller University, Stephen Kent continued research there as an assistant professor through 1981. He has also held faculty positions at the California Institute of Technology, Bond University in Australia, and The Scripps Research Institute in California. Currently, Stephen Kent is Professor Emeritus of Biochemistry and Molecular Biology and Professor Emeritus of Chemistry at the University of Chicago, where from 2003-2009 he served as Director of the Institute for Biophysical Dynamics. In addition to his academic achievements, in the 1990s Kent was the founder of two San Francisco Bay Area biotech companies: Ciphergen Biosytems and Gryphon Sciences. Stephen Kent has received international recognition for his research achievements.
Coevolution between parasite and host can lead to hosts becoming resistant to the parasites or the parasites may evolve greater virulence, leading to immunopathological disease. Human activity is involved with many emerging infectious diseases, such as environmental change enabling a parasite to occupy new niches. When that happens, a pathogen that had been confined to a remote habitat has a wider distribution and possibly a new host organism. Parasites jumping from nonhuman to human hosts are known as zoonoses. Under disease invasion, when a parasite invades a new host species, it may become pathogenic in the new host. Several human activities have led to the emergence of zoonotic human pathogens, including viruses, bacteria, protozoa, and rickettsia, and spread of vector-borne diseases, see also globalization and disease and wildlife disease:
==== Other chemistry and biochemistry ==== Amalgam (chemistry), represented in medieval alchemical texts with "aaa" Asymmetric allylic alkylation α-Aminoadipate pathway, for the synthesis of the amino acid L-lysine AAA proteins (ATPases Associated with various cellular Activities)
Sources: en.wikipedia.org
1.1 L (1071 cc) E1, 1 barrel, 55 PS (40 kW; 54 hp) / 79 N⋅m (58 lb⋅ft) 1.3 L (1296 cc) E3, 2 barrel, 68 PS (50 kW; 67 hp) / 95 N⋅m (70 lb⋅ft) 1.5 L (1490 cc) E5, 2 barrel, 75 PS (55 kW; 74 hp) / 115 N⋅m (85 lb⋅ft) 1.5 L (1490 cc) E5S, 2x2 barrel, 88 PS (65 kW; 87 hp) / 120 N⋅m (89 lb⋅ft) The most powerful version was marketed as the "323 GT" in European markets. The Familia/323 underwent a facelift in January 1983. For the Japanese market other top end models were offered, originally the three-door Familia XGI with a 1,500 cc single cam, multi-point fuel-injected engine. In June 1983 the turbocharged XGI Turbo was added, Mazda's first turbocharged piston engine. It had a particularly small turbocharger, for better low-end response. Period commentators complimented its linear and smooth power delivery. The XG Turbo also received a suitably updated chassis and wheels to handle the 115 PS (85 kW). The Familia saloon and their twin, the Ford Laser S, was also offered with the same specifications but in limited numbers. Claimed outputs in the Japanese market were considerably higher than in export countries, due to the differing JIS standard rather than DIN. Period sources suggest subtracting ten percent from the JIS numbers. This particular Familia was a strong comeback for Mazda in the Japanese market, even outselling the Toyota Corolla on several occasions. The four-door saloon was equipped with a reverse-rake front grille and lights in the Japanese market, to make it appear more "senior". The same front design was used for the GA/GB Ford Meteor.
American biochemist of Ukrainian-Jewish origin, who discovered metabolic regulation by feedback inhibition. Henry Berkeley Franks (Hal) Dixon (1928–2008). British enzymologist at the University of Cambridge. Malcolm Dixon FRS (1899–1985). British biochemist at the University of Cambridge. Research on enzyme structure, kinetics, and properties. His book (with Edwin C. Webb) Enzymes was very influential.
=== Flight-time equivalent dose === Natural background radiation typically increases with altitude above the earth's surface. Utilizing this phenomenon, dose resulting from radiological exposures can be expressed in units of flight-time. Flight-time equivalent dose is defined as the time spent in an aircraft at cruising altitude required to receive a radiological dose approximately equivalent to a radiological exposure such as a medical x-ray. One hour of flight-time is approximately equivalent to a dose of 0.004 millisieverts.
In classical SELEX, the process of randomized single stranded library generation, target incubation, and binding sequence elution and amplification described above are repeated until the vast majority of the retained pool consists of target binding sequences, though there are modifications and additions to the procedure that are often used, which are discussed below.
In his normal life, he is a quiet programmer for the "respectable software company" Meta Cortex, while in private, he is a computer hacker who penetrates computer systems illicitly and steals information under his hacker alias "Neo". He also sells illegal untraceable computer systems and hacking programs along with controlling computer viruses stashed on CDs and diskettes. During his time as a hacker, Anderson has learned about something known only as "The Matrix". During the years prior to the events of The Matrix, Neo has spent his time trying to find the one man who he thought could tell him what the Matrix was, a supposed terrorist known only as Morpheus. After an encounter with another hacker, Trinity, Anderson is suddenly contacted by Morpheus via a cell phone mailed to his office, but is almost immediately captured by the virtual reality's Agents, led by Agent Smith. After refusing to cooperate with the agents, Neo has an electronic bug implanted within his Matrix-simulated body so that his actions can be tracked, and those seeking to make contact from the free world can be traced and destroyed. He is then contacted by Trinity, freed from the bug, and taken to meet Morpheus. Neo is offered a choice to remain in his everyday life and forget about the Matrix or to learn what the Matrix really is. Choosing the latter option, he takes a drug (commonly called the "red pill"), which is actually a program designed to disrupt his mind's neural connection to the Matrix and make it easier for his real body to be found and awakened in the real world.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.